EXTON, Pa., Jan. 28 /PRNewswire/ -- BioTrends Research Group, Inc. released its Fourth Annual Nephrology TreatmentTrends Publication, a syndicated report offering comprehensive insight into the management of renal anemia and bone and mineral metabolism in Chronic Kidney Disease (CKD). The report is based on responses to an online survey, completed by 305 clinical nephrologists in the US, during December 2007.
In the anemia market, the vast majority of nephrologists report being aware of safety concerns surrounding the use of ESAs and 80% indicate that these safety issues have had an impact on their management of anemia, primarily reflected in their lower hemoglobin targets. More than three quarters of the nephrologists state that they do not anticipate any further changes. Amgen's Epogen continues its position as market share leader in dialysis while Aranesp and Procrit continue to battle for market leader position in pre-dialysis.
In the IV Iron market, use continues to be primarily reserved for hemodialysis patients with the majority of nephrologists viewing American Regent's Venofer and Watson's Ferrlecit as interchangeable. AMAG Pharmaceuticals recently filed an NDA for a new form of intravenous iron, ferumoxytol, which could be commercially available in the second half of 2008. Current familiarity with ferumoxytol is low, with 68% indicating that they are "not at all familiar" with the product.
In the phosphate binder market, nephrologists seem to be in agreement
about the importance of controlling phosphorus in pre-dialysis patients,
with 62% reporting "phosphorus" as the most important level to keep within
target range (over PTH and calcium). This has not, however, translated into
increased use of binders over the past year. Binder preference also remains
similar to last year with calcium-based binders (such as Fresenius Medical
Care's PhosLo) dominating 2:1 in the pre-dialysis setting, whereas in the
dialysis market, the shift to
|SOURCE BioTrends Research Group, Inc.|
Copyright©2008 PR Newswire.
All rights reserved